Literature DB >> 17785750

Cementless fixation of megaprostheses using a conical fluted stem in the treatment of bone tumours.

J Bruns1, G Delling, H Gruber, C H Lohmann, C R Habermann.   

Abstract

We reviewed 25 patients in whom a MUTARS megaprosthesis with a conical fluted stem had been implanted. There were three types of stem: a standard stem was used in 17 cases (three in the proximal femur, nine in the distal femur and five proximal tibia), a custom-made proximal femoral stem in four cases and a custom-made distal femoral stem in four cases. The mean age of the patients was 40.1 years (17 to 70) and the mean follow-up was for 2.5 years (0.9 to 7.4). At follow-up two patients had died from their disease: one was alive with disease and 22 were disease-free. One of 23 prostheses had been removed for infection and another revised to a cemented stem. The mean Musculoskeletal Tumor Society score was 24.9 (12 to 30) and the mean Karnofsky index was 82% (60% to 100%). There was no radiological evidence of loosening or subsidence. Stem stress shielding was seen in 11 patients and was marked in five of these. There were five complications, rupture of the extensor mechanism of the knee after extra-articular resection in two patients, deep venous thrombosis in one, septic loosening in one, and dislocation of the hip in one. The survival rate after seven years was 87% (95% confidence interval (CI) 83 to 91) for the patients and 95% (95% CI 91 to 99) for the megaprosthesis. A longer follow-up is needed to confirm these encouraging results.

Entities:  

Mesh:

Year:  2007        PMID: 17785750     DOI: 10.1302/0301-620X.89B8.19236

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  10 in total

1.  [Megaprostheses of the knee joint].

Authors:  K Anagnostakos; D Kohn
Journal:  Orthopade       Date:  2010-10       Impact factor: 1.087

Review 2.  "Advances in the surgical management of bone tumors".

Authors:  Justin E Bird
Journal:  Curr Oncol Rep       Date:  2014-07       Impact factor: 5.075

Review 3.  Megaprosthesis versus Allograft Prosthesis Composite for massive skeletal defects.

Authors:  Deepak Gautam; Rajesh Malhotra
Journal:  J Clin Orthop Trauma       Date:  2017-09-25

4.  Hydroxyapatite-coated collars reduce radiolucent line progression in cemented distal femoral bone tumor implants.

Authors:  Melanie J Coathup; Anish Sanghrajka; William J Aston; Panagiotis D Gikas; Robin C Pollock; Stephen R Cannon; John A Skinner; Timothy W R Briggs; Gordon W Blunn
Journal:  Clin Orthop Relat Res       Date:  2015-01-30       Impact factor: 4.176

5.  Osteointegration in Compliant Self-Adjusting Compression Fixation Shown by Backscatter Electron Microscopy: A Case Report.

Authors:  Alexander B Christ; Elexis Baral; Timothy M Wright; John H Healey
Journal:  HSS J       Date:  2019-06-11

6.  A new technique of endoprosthetic replacement for osteosarcoma of proximal femur with intra-articular extension.

Authors:  E Oragui; M Nannaparaju; K Sri-Ram; W Khan; A Hashemi-Nejad; J Skinner
Journal:  Int J Surg Case Rep       Date:  2012-10-13

7.  Computer navigation and distal femoral reconstruction in the oncologic patient.

Authors:  Brian T Palumbo; Eric Henderson; Justin Rizer; Douglas G Letson; David Cheong
Journal:  J Orthop       Date:  2017-03-23

8.  Interlocking reconstruction-mode stem-sideplates preserve at-risk hips with short residual proximal femora.

Authors:  Alexander B Christ; Tomohiro Fujiwara; Mohamed A Yakoub; John H Healey
Journal:  Bone Joint J       Date:  2021-02       Impact factor: 5.082

9.  Compress knee arthroplasty has 80% 10-year survivorship and novel forms of bone failure.

Authors:  John H Healey; Carol D Morris; Edward A Athanasian; Patrick J Boland
Journal:  Clin Orthop Relat Res       Date:  2013-03       Impact factor: 4.176

10.  Modular cementless prosthetic reconstruction after resection of lower extremity malignant tumor.

Authors:  Senol Bekmez; Mehmet Ayvaz; Altug Yucekul; Mazhar Tokgozoglu
Journal:  Acta Orthop Traumatol Turc       Date:  2016-12-10       Impact factor: 1.511

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.